Pathway-specific polygenic risk scores correlate with clinical status and Alzheimer's-related biomarkers.

ABSTRACT: Background: APOE is the largest genetic risk factor for sporadic Alzheimer's disease (AD), but there is a substantial polygenic component as well. Polygenic risk scores (PRS) can summarize small effects across the genome but may obscure differential risk associated with different molecular processes and pathways. Variability at the genetic level may contribute to the extensive phenotypic heterogeneity of Alzheimer's disease (AD). Here, we examine polygenic risk impacting specific pathways associated with AD and examined its relationship with clinical status and AD biomarkers of amyloid, tau, and neurodegeneration (A/T/N). Methods: A total of 1,411 participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI) with genotyping data were included. Sets of varian

SUBMITTER: Schork NJ 

PROVIDER: S-EPMC10002839 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature